When it comes to pharmaceuticals, the effectiveness of a medicine is a complex issue, determined by more than just its chemical structure. Drugs Bioavailability is the key metric. For every pharmaceutical professional, researcher, and contract manufacturing partner, understanding drugs bioavailability is not only important for academic purposes; it is the connection between the pill you take and its effect.

Drugs Bioavailability can play both roles of hero and villain in drug delivery. Bioavailability determines how much of a dose should be given and what type of formulation is needed. Ultimately, it determines whether the drug will be successful or fail in clinical trials and on the market.

This data will provide an in-depth look at what drugs bioavailability means in pharmacy. It will also provide a detailed explanation of the complicated calculations and reveal the many factors that can limit bioavailability. Furthermore, it will illustrate the importance of working with partners, particularly third-party pharma manufacturing company in India, to develop effective solutions to this complex challenge.

Table of Contents

Defining the Critical Metric – Bioavailability of Drug

What is Bioavailability?

An easy definition of the bioavailability of a drug is how much of an administered dose of a drug actually reaches the bloodstream unchanged, so that it can perform its intended function(s). A drug given through the intravenous (IV) route is considered to be 100% bioavailable since the drug goes straight into the bloodstream without having to pass through any barriers between the injection site and the bloodstream.

With oral administration, the bioavailability of almost all drugs is considerably less than 100% since the drug has to survive numerous biological processes that take place between the ingestion of the drug (in pill form or capsule) and its absorption into the bloodstream. A drug that has high bioavailability for a patient allows for a lower effective dose of the medication to be used by the patient’s body.

Quick Enquiry

Send Us a Message

Chat with us

The Pharmacokinetic Journey (ADME)

Drugs Bioavailability is the “A” in the Pharmacokinetic acronym ADME, which represents the direction of a drug through the body –

Absorption (Drug enters the bloodstream)
Distribution (Drug travels to tissues and sites of action)
Metabolism (Drug is chemically altered, usually for deactivation)
Excretion (Drug is removed from the body)

Drugs Bioavailability is mainly governed by the first two stages a drug encounters: Absorption from the GI tract and First-Pass Metabolism in the liver.

The Barriers – Factors Affecting Bioavailability

The journey for oral medications to enter the bloodstream is a treacherous one. Reasons for the low drugs bioavailability of most orally administered medications fall under two major categories: The physicochemical properties of the drug and patient physiology.

1. Physicochemical properties of the drug

These characteristics are unique to the molecular structure, and they represent the first barrier that the drug must cross to get into circulation.

Solubility or dissolution rate – For a drug to be absorbed into the bloodstream, the drug must be dissolved in the gastrointestinal (GI) fluids before it can be absorbed. Because poorly water-soluble drugs are often poorly absorbed, they tend to have a lower drugs bioavailability compared to other drugs.

Permeability – Once the drug has dissolved, it needs to pass through the lipid (fatty) membranes that line the intestine. A drug that contains many polar (water-soluble) or non-polar (fat-soluble) molecules will find it difficult to pass through these membranes.

Chemical stability – There are some instances where the chemical structure of a drug is destroyed due to its exposure to an extremely acidic environment, such as the stomach, or due to exposure to digestive enzymes. As a result, the drug cannot be absorbed, leading to diminished drugs bioavailability.

2. Biological Barriers (The First-Pass Effect)

The primary factor contributing to low drugs bioavailability is –

Gut Wall Metabolism – As a drug is absorbed, it may begin to be metabolized by the gastrointestinal tract due to enzyme activity (intestinal wall originates from the gut) before reaching systemic circulation.

Hepatic First-Pass Metabolism – Drugs absorbed via the portal vein immediately go to the liver for metabolism. The liver has all the enzymes (Cytochrome P-450 system) necessary to convert the active forms of [doses] into inactive compounds that cannot be utilized systemically. High levels of first-pass metabolism will dramatically reduce the availability of that particular dose.

3. Patient-Related Factors

There are many reasons as to why one patient may have different levels of availability to the same dose, including.

Gastric Emptying Rate – This refers to how quickly an individual can move food products from the stomach into the small intestine (where most absorption occurs).

Food Effects – Depending on its composition and properties, food may enhance (by increased blood flow) or inhibit (via binding) absorption.

Disease States – In patients with liver or renal impairments, overall exposure to a drug may be altered.

The Manufacturing Solution – Enhancing Bioavailability

The greatest opportunities for overcoming issues with the drugs bioavailability of drugs are in the areas of both formulation science and pharmaceutical manufacturing. This is where the true expertise of contract manufacturing in pharmaceutical industry becomes apparent.

1. The Role of Formulation Science

There are several advanced formulation techniques that have been developed to help overcome the physicochemical barriers to drugs bioavailability.

These techniques include –

Micronization/Nanonization – This technique reduces the drug’s particle size, thereby increasing drug surface area and improving dissolution and absorption, by utilizing the extreme increase in drug surface area when compared to a drug that is larger in size.

Lipid-Based Drug Delivery Systems (LBDDS) – By encapsulating drugs with poor solubility within a lipid or oil, the drug can bypass the dissolution stage of the absorption process, and instead, a majority of the drug may be delivered to the bloodstream via the lymphatic system, in many cases, thereby avoiding the metabolic process of first-pass liver metabolism.

Solid Dispersion – The drug is mixed with a hydrophilic polymer carrier to improve solubility via wetting action.

Pro-drugs – The drug is chemically altered to an inactive pro-drug form to allow for more effective transport through the GI tract and into the bloodstream for conversion back to its active drug form.

2. The Strategic Partner – Third-Party Pharma Manufacturing Company in India

For pharmaceutical companies, leveraging the capabilities of an established and experienced third-party pharma manufacturing companies is a strategic way to address the Bioavailability Challenge.

Access to Technology and Expertise – The leading manufacturers in India provide the latest equipment and support teams who specialize in developing new Complex Pharmaceutical Formulations (CPFs). Small and medium-sized pharmaceutical manufacturing businesses may not have access to this expertise and advanced manufacturing equipment.

Quality Manufacturing Compliance – Reputable contract manufacturing in pharmaceutical industry maintains compliance with the World Health Organization (WHO) Good Manufacturing Practices (GMP). By adhering to the WHO Guidelines, contract manufacturing partners will consistently produce high-quality CPFs in a consistent and dependable manner.

Bioequivalence – During the development of generic pharmaceuticals, the manufacturer is responsible for establishing that the generic product is Bioequivalent to the originator (innovator) or branded product. This means that the generic drug has a similar time reflecting the rate and degree (extent) of the absorption of the generic pharma product is equal to that of the originator’s product.

Cost-Effective Growth – Upon developing the best advanced High Bioavailable Formulation, a large third-party pharma manufacturing company in India has the ability to rapidly and economically scale up production to fulfill the needs of the global market, an important aspect of accelerating Entry to Market.

Conclusion

The bioavailability of drug substances is a key element of a successful medication. It encompasses every stage of a drug’s journey—from the laboratory bench and manufacturing plant to the patient’s body and final clinical outcome.

When pharmaceutical professionals focus on drug bioavailability, they address three critical areas. First, determining the appropriate dosage required to maintain plasma concentration within the therapeutic window, balancing minimum effective and toxic levels. Second, adopting innovative production methods that enhance solubility, permeability, and resistance to first-pass metabolism.

Third, building strategic partnerships with experienced pharmaceutical manufacturers is essential. Collaborating with trusted contract manufacturing experts like Medella Softgel, recognized as the Best Pharma Company in India, enables the production of high-quality, bioequivalent products while benefiting from advanced technologies and cost efficiencies offered by third-party pharma manufacturing.

Also Read: Difference Between API Manufacturing and Drug Formulation